Published in Pharm Res on February 01, 2003
Endocytosis of nanomedicines. J Control Release (2010) 3.23
Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater (2009) 2.87
Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn (2009) 2.35
Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev (2007) 1.92
High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. Proc Natl Acad Sci U S A (2008) 1.82
The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials (2009) 1.82
More effective nanomedicines through particle design. Small (2011) 1.80
Evaluating the intracellular stability and unpacking of DNA nanocomplexes by quantum dots-FRET. J Control Release (2006) 1.64
Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. Mol Pharm (2009) 1.61
Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines (2010) 1.57
Endocytosis and exocytosis of nanoparticles in mammalian cells. Int J Nanomedicine (2014) 1.34
PLGA nanoparticle--peptide conjugate effectively targets intercellular cell-adhesion molecule-1. Bioconjug Chem (2007) 1.31
Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small (2008) 1.31
Logic-embedded vectors for intracellular partitioning, endosomal escape, and exocytosis of nanoparticles. Small (2010) 1.19
Intracellular trafficking of silicon particles and logic-embedded vectors. Nanoscale (2010) 1.15
Quantification of the force of nanoparticle-cell membrane interactions and its influence on intracellular trafficking of nanoparticles. Biomaterials (2008) 1.14
Poly(omega-pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery. Biomaterials (2009) 1.12
Nanovehicular intracellular delivery systems. J Pharm Sci (2008) 1.10
Cellular and extracellular programming of cell fate through engineered intracrine-, paracrine-, and endocrine-like mechanisms. Biomaterials (2011) 1.08
Antigen delivery with poly(propylacrylic acid) conjugation enhances MHC-1 presentation and T-cell activation. Bioconjug Chem (2009) 1.06
Docetaxel Loaded PEG-PLGA Nanoparticles: Optimized Drug Loading, In-vitro Cytotoxicity and In-vivo Antitumor Effect. Iran J Pharm Res (2014) 1.03
Shear-regulated uptake of nanoparticles by endothelial cells and development of endothelial-targeting nanoparticles. J Biomed Mater Res A (2010) 1.03
Tracking mesenchymal stem cells with iron oxide nanoparticle loaded poly(lactide-co-glycolide) microparticles. Nano Lett (2012) 1.02
Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T-cell production and prophylactic vaccine efficacy. Bioconjug Chem (2010) 1.00
Unambiguous observation of shape effects on cellular fate of nanoparticles. Sci Rep (2014) 1.00
Engineering cells with intracellular agent-loaded microparticles to control cell phenotype. Nat Protoc (2014) 0.99
Surface modification of PLGA nanoparticles via human serum albumin conjugation for controlled delivery of docetaxel. Daru (2013) 0.98
Surface functionality of nanoparticles determines cellular uptake mechanisms in mammalian cells. Small (2012) 0.94
Biodegradable nanoparticles mimicking platelet binding as a targeted and controlled drug delivery system. Int J Pharm (2011) 0.94
Engineering mesenchymal stem cells for regenerative medicine and drug delivery. Methods (2015) 0.93
Diaminobenzidine photoconversion is a suitable tool for tracking the intracellular location of fluorescently labelled nanoparticles at transmission electron microscopy. Eur J Histochem (2012) 0.93
Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content. Int J Nanomedicine (2012) 0.90
Understanding nonviral nucleic acid delivery with quantum dot-FRET nanosensors. Nanomedicine (Lond) (2012) 0.88
Kinetic analysis of nanoparticulate polyelectrolyte complex interactions with endothelial cells. Biomaterials (2007) 0.88
Nanoparticles for local drug delivery to the oral mucosa: proof of principle studies. Pharm Res (2010) 0.88
Relevance of biophysical interactions of nanoparticles with a model membrane in predicting cellular uptake: study with TAT peptide-conjugated nanoparticles. Mol Pharm (2009) 0.88
Cellular interaction of folic acid conjugated superparamagnetic iron oxide nanoparticles and its use as contrast agent for targeted magnetic imaging of tumor cells. Int J Nanomedicine (2012) 0.87
Investigation of Polyethylenimine/DNA Polyplex Transfection to Cultured Cells Using Radiolabeling and Subcellular Fractionation Methods. Mol Pharm (2013) 0.86
Intracellular uptake and trafficking of difluoroboron dibenzoylmethane-polylactide nanoparticles in HeLa cells. ACS Nano (2010) 0.86
Studies of the cellular uptake of hydrogel nanospheres and microspheres by phagocytes, vascular endothelial cells, and smooth muscle cells. J Biomed Mater Res A (2009) 0.85
Modular plasmonic nanocarriers for efficient and targeted delivery of cancer-therapeutic siRNA. Nano Lett (2014) 0.84
Visualization of internalization of functionalized cobalt ferrite nanoparticles and their intracellular fate. Int J Nanomedicine (2013) 0.84
Nanoparticle-mediated p53 gene therapy for tumor inhibition. Drug Deliv Transl Res (2011) 0.84
cIBR effectively targets nanoparticles to LFA-1 on acute lymphoblastic T cells. Mol Pharm (2010) 0.84
Niemann-Pick C1 affects the gene delivery efficacy of degradable polymeric nanoparticles. ACS Nano (2014) 0.81
Anti-tumor effects of brucine immuno-nanoparticles on hepatocellular carcinoma. Int J Nanomedicine (2012) 0.81
Interfacial activity assisted surface functionalization: a novel approach to incorporate maleimide functional groups and cRGD peptide on polymeric nanoparticles for targeted drug delivery. Mol Pharm (2010) 0.81
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PLoS One (2013) 0.81
Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles. Biomaterials (2011) 0.80
Biomechanics and thermodynamics of nanoparticle interactions with plasma and endosomal membrane lipids in cellular uptake and endosomal escape. Langmuir (2014) 0.80
Towards comprehensive cardiac repair and regeneration after myocardial infarction: Aspects to consider and proteins to deliver. Biomaterials (2015) 0.80
Labeling the oily core of nanocapsules and lipid-core nanocapsules with a triglyceride conjugated to a fluorescent dye as a strategy to particle tracking in biological studies. Nanoscale Res Lett (2014) 0.79
Bioenergetic failure correlates with autophagy and apoptosis in rat liver following silver nanoparticle intraperitoneal administration. Part Fibre Toxicol (2013) 0.79
Cellular communication via nanoparticle-transporting biovesicles. Nanomedicine (Lond) (2013) 0.79
Development of drug loaded nanoparticles for tumor targeting. Part 2: Enhancement of tumor penetration through receptor mediated transcytosis in 3D tumor models. Nanoscale (2013) 0.79
Nanoencapsulation of natural triterpenoid celastrol for prostate cancer treatment. Int J Nanomedicine (2015) 0.77
Investigation of endocytosis and cytotoxicity of poly-d, l-lactide-poly(ethylene glycol) micro/nano-particles in osteoblast cells. Int J Nanomedicine (2010) 0.77
Cell type-specific response to high intracellular loading of polyacrylic acid-coated magnetic nanoparticles. Int J Nanomedicine (2015) 0.77
Regulating exocytosis of nanoparticles via host-guest chemistry. Org Biomol Chem (2015) 0.77
Membrane expression of MRP-1, but not MRP-1 splicing or Pgp expression, predicts survival in patients with ESFT. Br J Cancer (2013) 0.77
Magnetic Resonance Detection of CD34+ Cells from Umbilical Cord Blood Using a 19F Label. PLoS One (2015) 0.77
Imaging the intracellular degradation of biodegradable polymer nanoparticles. Beilstein J Nanotechnol (2014) 0.77
Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier. Curr Pharm Des (2016) 0.76
Ultrapure laser-synthesized Si-based nanomaterials for biomedical applications: in vivo assessment of safety and biodistribution. Sci Rep (2016) 0.76
Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide. Mol Pharm (2015) 0.76
Surfactant-free formulation of poly(lactic/glycolic) acid nanoparticles encapsulating functional polypeptide: a technical note. AAPS PharmSciTech (2009) 0.75
Cellular uptake and fate of fibroin microspheres loaded with randomly fragmented DNA in 3T3 cells. Int J Nanomedicine (2016) 0.75
Intracellular trafficking and cellular uptake mechanism of PHBV nanoparticles for targeted delivery in epithelial cell lines. J Nanobiotechnology (2017) 0.75
Fate of cerium dioxide nanoparticles in endothelial cells: exocytosis. J Nanopart Res (2015) 0.75
Dynamic nano-imaging of label-free living cells using electron beam excitation-assisted optical microscope. Sci Rep (2015) 0.75
Transient loading of CD34(+) hematopoietic progenitor cells with polystyrene nanoparticles. Int J Nanomedicine (2017) 0.75
Inhibition of bone loss with surface-modulated, drug-loaded nanoparticles in an intraosseous model of prostate cancer. J Control Release (2016) 0.75
Feasibility Study of the Permeability and Uptake of Mesoporous Silica Nanoparticles across the Blood-Brain Barrier. PLoS One (2016) 0.75
Fabrication and biological evaluation of chitosan coated hyaluronic acid-docetaxel conjugate nanoparticles in CD44(+) cancer cells. Daru (2016) 0.75
Intracellular disposition of chitosan nanoparticles in macrophages: intracellular uptake, exocytosis, and intercellular transport. Int J Nanomedicine (2017) 0.75
A Comparison of Hepatocyte Cytotoxic Mechanisms for Docetaxel and PLGA-Docetaxel Nanoparticls. Iran J Pharm Res (2017) 0.75
Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev (2003) 7.08
Nanotech approaches to drug delivery and imaging. Drug Discov Today (2003) 3.63
Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J (2002) 3.13
Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm (2005) 3.08
Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Mol Pharm (2008) 2.90
Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release (2002) 2.52
Characterization of nanoparticle uptake by endothelial cells. Int J Pharm (2002) 2.13
3-D tumor model for in vitro evaluation of anticancer drugs. Mol Pharm (2008) 2.11
Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm (2002) 2.06
Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev (2007) 1.92
Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. J Control Release (2003) 1.72
Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. Biomaterials (2008) 1.70
Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer (2004) 1.60
Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-co-glycolide) nanoparticles. Int J Pharm (2003) 1.57
Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm (2005) 1.55
Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion. Cancer Lett (2013) 1.43
The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm Res (2004) 1.42
Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. J Pharm Sci (2004) 1.28
TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials (2008) 1.28
Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury. FASEB J (2009) 1.26
Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol Pharm (2004) 1.23
Magnetic resonance imaging of multifunctional pluronic stabilized iron-oxide nanoparticles in tumor-bearing mice. Biomaterials (2009) 1.19
Critical determinants in PLGA/PLA nanoparticle-mediated gene expression. Pharm Res (2004) 1.18
Quantification of the force of nanoparticle-cell membrane interactions and its influence on intracellular trafficking of nanoparticles. Biomaterials (2008) 1.14
Targeted drug delivery in cancer therapy. Technol Cancer Res Treat (2005) 1.13
PEG-functionalized magnetic nanoparticles for drug delivery and magnetic resonance imaging applications. Pharm Res (2010) 1.11
Biophysical interactions with model lipid membranes: applications in drug discovery and drug delivery. Mol Pharm (2009) 1.11
Targeting intracellular targets. Curr Drug Deliv (2004) 1.07
Effect of molecular structure of cationic surfactants on biophysical interactions of surfactant-modified nanoparticles with a model membrane and cellular uptake. Langmuir (2009) 1.06
Targeting anti-HIV drugs to the CNS. Expert Opin Drug Deliv (2009) 1.05
Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids. Mol Pharm (2010) 1.05
Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells. Mol Pharm (2005) 1.04
Optical imaging and magnetic field targeting of magnetic nanoparticles in tumors. ACS Nano (2010) 1.02
Clathrin and caveolin-1 expression in primary pigmented rabbit conjunctival epithelial cells: role in PLGA nanoparticle endocytosis. Mol Vis (2003) 1.00
Inhibition of apoptosis through localized delivery of rapamycin-loaded nanoparticles prevented neointimal hyperplasia and reendothelialized injured artery. Circ Cardiovasc Interv (2008) 0.98
Oh the irony: Iron as a cancer cause or cure? Biomaterials (2011) 0.98
Tumor ablation and nanotechnology. Mol Pharm (2010) 0.98
Characterization of porous PLGA/PLA microparticles as a scaffold for three dimensional growth of breast cancer cells. Biomacromolecules (2005) 0.97
Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stress. Appl Biochem Biotechnol (2008) 0.95
Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles. Adv Drug Deliv Rev (2013) 0.90
Polymeric nanoparticles for gene delivery. Expert Opin Drug Deliv (2006) 0.89
Biophysical characterization of nanoparticle-endothelial model cell membrane interactions. Mol Pharm (2008) 0.89
Advances in stroke therapy. Drug Deliv Transl Res (2011) 0.88
Relevance of biophysical interactions of nanoparticles with a model membrane in predicting cellular uptake: study with TAT peptide-conjugated nanoparticles. Mol Pharm (2009) 0.88
Epigenetic modulation of the biophysical properties of drug-resistant cell lipids to restore drug transport and endocytic functions. Mol Pharm (2012) 0.86
Nanoparticles: cellular uptake and cytotoxicity. Adv Exp Med Biol (2014) 0.85
Codelivery of DNA and siRNA via arginine-rich PEI-based polyplexes. Mol Pharm (2015) 0.84
Nanoparticle-mediated p53 gene therapy for tumor inhibition. Drug Deliv Transl Res (2011) 0.84
Selective biophysical interactions of surface modified nanoparticles with cancer cell lipids improve tumor targeting and gene therapy. Cancer Lett (2013) 0.83
Nanoparticles for delivery of chemotherapeutic agents to tumors. Curr Opin Investig Drugs (2007) 0.81
Optical imaging to map blood-brain barrier leakage. Sci Rep (2013) 0.81
Nanoparticles for imaging, diagnosis, and therapeutics. Mol Pharm (2009) 0.80
Efficacy of Tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neurons. AIDS Res Hum Retroviruses (2011) 0.80
Erythropoietin induces excessive neointima formation: a study in a rat carotid artery model of vascular injury. J Cardiovasc Pharmacol Ther (2007) 0.80
Biomechanics and thermodynamics of nanoparticle interactions with plasma and endosomal membrane lipids in cellular uptake and endosomal escape. Langmuir (2014) 0.80
Preparation of biodegradable nanoparticles and their use in transfection. CSH Protoc (2008) 0.79
Heterogeneity in nanoparticles influences biodistribution and targeting. Nanomedicine (Lond) (2013) 0.78
Drug Resistant Breast Cancer Cell Line Displays Cancer Stem Cell Phenotype and Responds Sensitively to Epigenetic Drug SAHA. Drug Deliv Transl Res (2012) 0.77
Nanotechnology in urology. Urol Clin North Am (2009) 0.76
A novel approach for cancer immunotherapy: tumor cells with anchored superantigen SEA generate effective antitumor immunity. J Clin Immunol (2004) 0.76
Applications of nanoparticles in the detection and treatment of kidney diseases. Adv Chronic Kidney Dis (2013) 0.76
Advancements in the delivery of epigenetic drugs. Expert Opin Drug Deliv (2015) 0.75
Drug delivery to the testis: current status and potential pathways for the development of novel therapeutics. Drug Deliv Transl Res (2011) 0.75
10. Biophysics of cell membrane and nanoparticle interface: Original research article: Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake, 2002. J Control Release (2014) 0.75